Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kronisk subdural hæmatom embolisering med afkoblingsspiraler (SEED)

22. september 2026 opdateret af: Christopher P Kellner, Icahn School of Medicine at Mount Sinai

Sikkerhed og effektivitet af kronisk subdural hæmatom embolisering med udskillelige spiraler

This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).

Studieoversigt

Detaljeret beskrivelse

The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

150

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Arizona
      • Tucson, Arizona, Forenede Stater, 85711
        • Ikke rekrutterer endnu
        • Carondelet Neurological Institute
        • Ledende efterforsker:
          • Alexander Coon, MD
        • Kontakt:
    • California
      • San Deigo, California, Forenede Stater, 92093
        • Ikke rekrutterer endnu
        • University of California - San Deigo
        • Kontakt:
        • Ledende efterforsker:
          • David Santiago-Dieppa, MD
      • Walnut Creek, California, Forenede Stater, 94598
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40292
        • Ikke rekrutterer endnu
        • University of Louisville
        • Kontakt:
        • Ledende efterforsker:
          • Isaac Josh Abecassis, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Ikke rekrutterer endnu
        • Oklahoma University Medical Center
        • Ledende efterforsker:
          • Hakeem Shakir, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment

Beskrivelse

Inclusion criteria:

  • Age ≥ 18
  • Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
  • A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
  • Signed informed consent obtained by patient or Legal Authorized Representative (LAR)

Exclusion criteria:

  • Primary acute SDH
  • Prior MMAE in target territory
  • Premorbid mRS > 3
  • Common carotid stenosis >70% or prior carotid stent placement
  • Significant medical contraindication to angiography (kidney failure/disease)
  • Anatomical variations that would make MMA embolization difficult or unsafe
  • Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
  • Pregnancy
  • Life expectancy ≤ 1 year

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Participants with cSDH

All participants enrolled will be treated with the Balt coils.

  1. MMA embolization: Utilize Balt Coils as stand-alone with or without other embolics treatment.

  2. MMA embolization: Utilize Balt Coils in combination with or without embolics in surgical or bedside evacuation, such as:

    1. MMA embolization in combination with Balt coils post-surgical debridement, or
    2. MMA embolization using Balt coils alone, pre- or post-surgical debridement.

MMA embolization utilizing Balt Coils

Andre navne:
  • Optima
  • OptiMax
  • OptiBlock
  • Optima-serielinjens udvidelser

surgical or bedside evacuation

pre or post-surgical debridement

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in hematoma volume
Tidsramme: 180 days

Change in hematoma volume based on CT imaging

180 days
Change in maximal thickness
Tidsramme: 180 days

Change in maximal thickness based on CT imaging

180 days
Change in midline shift
Tidsramme: 180 days

Change in midline shift (mm) based on CT imaging

180 days
Number of periprocedural major disabling stroke or any death
Tidsramme: 30 days

Number of periprocedural major disabling stroke or any death

30 days
Number of participants with symptomatic recurrence progression requiring retreatment
Tidsramme: 180 days

Number of participants with symptomatic recurrence progression of the SDH requiring retreatment

180 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
Tidsramme: 180 days

Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor

180 days
Number of Acute successful embolization of the target vessel
Tidsramme: Immediately post-procedure

Determination of successful embolization based on angiographic imaging

Immediately post-procedure
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
Tidsramme: 180 days

The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL.

180 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Christopher Kellner, Icahn School of Medicine at Mount Sinai
  • Ledende efterforsker: Benjamin Yim, John Muir Health
  • Ledende efterforsker: Alexander Coon, Carondelet Neurological Institute

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. juni 2026

Primær færdiggørelse (Anslået)

1. september 2028

Studieafslutning (Anslået)

1. september 2028

Datoer for studieregistrering

Først indsendt

5. december 2025

Først indsendt, der opfyldte QC-kriterier

5. december 2025

Først opslået (Faktiske)

18. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner